{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:14:44Z","timestamp":1792419284421,"version":"4.5.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple clinical trials have assessed de-escalation strategies from combined modality therapy (CMT) to chemotherapy-alone for the treatment of early-stage classical Hodgkin lymphoma (cHL), confirming similar outcomes. The application of these data to the real-world is limited, however. We conducted a retrospective, multicenter cohort study comparing CMT vs chemotherapy-alone in patients with early-stage cHL (stage IA-IIB) treated between January 2010 and December 2020. Positron emission tomography (PET) scans after chemotherapy cycle 2 (PET2) were independently reviewed by a nuclear radiologist (Deauville score \u22654, positive; \u22643, negative). Patient outcomes were compared by using an intention-to-treat analysis. Among 125 patients (CMT, n = 63; chemotherapy-alone, n = 62) with a median follow-up of 59.8 months (95% CI, 48.6-71.0), no differences in overall survival were observed (5-year overall survival, CMT 98.0% vs chemotherapy-alone 95.1%; log-rank test, P = .38). However, there was reduced progression-free survival (PFS) with chemotherapy-alone among all patients (2-year PFS, CMT 95.1% vs chemotherapy-alone 75.3%; log-rank test, P = .005) and in those with bulky (n = 43; log-rank test, P &amp;lt; .001), unfavorable (n = 81; log-rank test, P = .002), or PET2-positive (n = 15; log-rank test, P = .02) disease. No significant differences in PFS were seen for patients with non-bulky (log-rank test, P = .35), favorable (log-rank test, P = .62), or PET2-negative (log-rank test, P = .19) disease. Based on our real-world experience, CMT seems beneficial for patients with early-stage cHL, especially those with PET2-positive and unfavorable disease. Chemotherapy-alone regimens can lead to comparable outcomes for patients with favorable, non-bulky, or PET2-negative disease. We conclude that although results seen in clinical trials are replicated in certain patient subgroups, other subgroups not fitting trial criteria do poorly when radiotherapy is excluded.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007363","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T20:53:13Z","timestamp":1653598393000},"page":"4241-4250","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome"],"prefix":"10.1182","volume":"6","author":[{"given":"Karan L.","family":"Chohan","sequence":"first","affiliation":[{"name":"1Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Young","sequence":"additional","affiliation":[{"name":"2Department of Radiology, Mayo Clinic, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Lester","sequence":"additional","affiliation":[{"name":"3Department of Radiation Oncology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":false,"given":"Muhamad","family":"Alhaj Moustafa","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Phoenix, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-094X","authenticated-orcid":false,"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-5418","authenticated-orcid":false,"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"6Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana N.","family":"Micallef","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"issue":"2","key":"2022072115255063500_B1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"2022072115255063500_B2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.6004\/jnccn.2006.0022","article-title":"Favorable early-stage Hodgkin lymphoma","volume":"4","author":"Yahalom","year":"2006","journal-title":"J Natl Compr Canc Netw."},{"issue":"8","key":"2022072115255063500_B3","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/10428190802140873","article-title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy","volume":"49","author":"Myrehaug","year":"2008","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022072115255063500_B4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jnci\/85.1.25","article-title":"Breast cancer after treatment of Hodgkin\u2019s disease","volume":"85","author":"Hancock","year":"1993","journal-title":"J Natl Cancer Inst."},{"issue":"10","key":"2022072115255063500_B5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(05)70387-9","article-title":"Lung cancer after treatment for Hodgkin\u2019s lymphoma: a systematic review","volume":"6","author":"Lorigan","year":"2005","journal-title":"Lancet Oncol."},{"issue":"39","key":"2022072115255063500_B6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/EDBK_238799","article-title":"Relapsed and refractory classical Hodgkin lymphoma: keeping pace with novel agents and new options for salvage therapy","volume":"39","author":"Moskowitz","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"12","key":"2022072115255063500_B7","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/bloodadvances.2020004167","article-title":"Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma","volume":"5","author":"Dahi","year":"2021","journal-title":"Blood Adv."},{"issue":"16","key":"2022072115255063500_B8","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol."},{"issue":"31","key":"2022072115255063500_B9","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized Phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol."},{"issue":"17","key":"2022072115255063500_B10","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med."},{"issue":"11","key":"2022072115255063500_B11","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2015.07.633","article-title":"Outcomes after chemotherapy followed by radiation for stage IIB Hodgkin lymphoma with bulky disease","volume":"15","author":"Reddy","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"10","key":"2022072115255063500_B12","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","article-title":"Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes","volume":"101","author":"Kumar","year":"2016","journal-title":"Haematologica."},{"issue":"11","key":"2022072115255063500_B13","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther."},{"issue":"3","key":"2022072115255063500_B14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/j.seminhematol.2016.05.005","article-title":"Clinical presentation and staging of Hodgkin lymphoma","volume":"53","author":"Gallamini","year":"2016","journal-title":"Semin Hematol."},{"issue":"15","key":"2022072115255063500_B15","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2017-10-772665","article-title":"Balancing risk and benefit in early-stage classical Hodgkin lymphoma","volume":"131","author":"Br\u00f6ckelmann","year":"2018","journal-title":"Blood."},{"key":"2022072115255063500_B16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"2022072115255063500_B17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/10428194.2021.1872069","article-title":"The presence of a bulky mediastinal mass of 7\u2009cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET\/CT","volume":"62","author":"Lopez-Alonso","year":"2021","journal-title":"Leuk Lymphoma."},{"key":"2022072115255063500_B18","first-page":"CD012643","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","volume":"9","author":"Aldin","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"2022072115255063500_B19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood."},{"key":"2022072115255063500_B20","author":"National Comprehensive Cancer Network"},{"key":"2022072115255063500_B21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2019-124866","article-title":"Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged \u226560 years","volume":"134","author":"Yasenchak","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2022072115255063500_B22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med."},{"issue":"6","key":"2022072115255063500_B23","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol."},{"key":"2022072115255063500_B24","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2021.39.15_suppl.7507","article-title":"CALGB 50801 (Alliance): PET adapted therapy in bulky stage I\/II classic Hodgkin lymphoma (cHL)","volume":"39","author":"LaCasce","year":"2021","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022072115255063500_B25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/10428194.2019.1663419","article-title":"Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era","volume":"61","author":"Taparra","year":"2020","journal-title":"Leuk Lymphoma."},{"issue":"30","key":"2022072115255063500_B26","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J Clin Oncol."},{"issue":"25","key":"2022072115255063500_B27","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"issue":"9","key":"2022072115255063500_B28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1200\/JCO.18.01652","article-title":"Relapse risk and loss of lifetime after modern combined modality treatment of young patients with Hodgkin lymphoma: a Nordic Lymphoma Epidemiology Group Study","volume":"37","author":"Biccler","year":"2019","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022072115255063500_B29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.16232","article-title":"No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy","volume":"188","author":"Lagerl\u00f6f","year":"2020","journal-title":"Br J Haematol."},{"issue":"13","key":"2022072115255063500_B30","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1200\/JCO.21.02407","article-title":"Limited, but not eliminated, excess long-term morbidity in stage I-IIA Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine and limited-field radiotherapy","volume":"40","author":"Lagerl\u00f6f","year":"2022","journal-title":"J Clin Oncol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4241\/1909091\/advancesadv2022007363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4241\/1909091\/advancesadv2022007363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T15:29:23Z","timestamp":1658417363000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/14\/4241\/485386\/A-real-world-study-of-combined-modality-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":30,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007363","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]}}}